Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 4/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.59 |
| ▸ | MERTK | Q12866 | 1/20 | 0.59 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.59 |
| ▸ | AXL | P30530 | 1/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975785 | 1.00 | PIK3CG (0.60) | PIK3CGPIK3CDMERTKPIK3R1AXL | |
| SCHEMBL30324496 | 1.00 | PIK3CG (0.60) | PIK3CGPIK3CDMERTKPIK3R1AXL | |
| SCHEMBL30133702 | 1.00 | PIK3CG (0.60) | PIK3CGPIK3CDMERTKPIK3R1AXL | |
| SCHEMBL15744216 | 0.91 | PIK3CD (0.61) | PIK3CGPIK3CDMERTKPIK3R1AXL | |
| SCHEMBL18308691 | 0.89 | PIK3CD (0.49) | PIK3CGPIK3CDMERTKPIK3R1AXL | |
| SCHEMBL975357 | 0.89 | PIK3CD (0.59) | PIK3CGPIK3CDMERTKPIK3R1AXL | |
| SCHEMBL25210611 | 0.89 | PIK3CG (0.64) | PIK3CGPIK3CDMERTKPIK3R1AXL | |
| SCHEMBL30324726 | 0.89 | PIK3CG (0.64) | PIK3CGPIK3CDMERTKPIK3R1AXL | |
| SCHEMBL25267326 | 0.89 | PIK3CG (0.64) | PIK3CGPIK3CDMERTKPIK3R1AXL | |
| SCHEMBL30133637 | 0.89 | PIK3CG (0.64) | PIK3CGPIK3CDMERTKPIK3R1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174556-A1 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-06-08 | — | — | US | disclosed |
| CN-115605481-A | Compounds as kinase inhibitors | 重庆复尚源创医药技术有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-04-23 | — | — | US | disclosed |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-04-23 | — | — | US | disclosed |
| US-10428087-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2019-10-01 | — | — | US | disclosed |
| US-8940752-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2448938-B1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORP (US) | 2014-05-28 | — | — | EP | disclosed |
| EP-2448938-B1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORP (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140066448-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2448938-A1 | PYRIMIDINONES AS PI3K INHIBITORS | Incyte Corporation (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
| WO-2011008487-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CG 4/4885PIK3CD 2/4885MERTK 550/4885 |
| US-10428087-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CG 4/4885PIK3CD 2/4885MERTK 550/4885 |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CG 4/4885PIK3CD 2/4885MERTK 550/4885 |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CG 4/4885PIK3CD 2/4885MERTK 550/4885 |
| US-20140066448-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PDPK1, PIK3CD | PIK3CG 12/4885PIK3CD 3/4885MERTK 708/4885 |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CG 4/4885PIK3CD 2/4885MERTK 550/4885 |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CG 4/4885PIK3CD 2/4885MERTK 550/4885 |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CG 4/4885PIK3CD 2/4885MERTK 550/4885 |
| US-20230174556-A1 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | PIK3CA, AKT1, PIK3CB | PIK3CG 5/4885PIK3CD 4/4885MERTK 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.